Enzyme Coupler Induced Pathway Silencing（ECLIPSE) technology is the exclusive scientific achievement of Dr. Hu Qi, one of the co-founders, addressing the issue of resistance mutations in anti-tumor drug molecules. A molecule employing the ECLIPSE strategy is a bifunctional entity, where a linker conjugates a "target protein ligand" with a "functional enzyme ligand". In other words, one end of the molecule can bind to the target protein of interest, while the other end can bind to an enzyme that modulates the function of proteins along a signaling pathway.